Dr. Mason is Director of the Cancer Imaging Program at UT Southwestern with over 20 year's experience in cancer imaging, therapy, and tumor pathophysiology. He is Professor of Radiology and member of the Simmons Comprehensive Cancer Center. He serves on faculty of graduate programs in Biomedical Engineering, Molecular Biophysics and Cancer Biology. Dr. Mason and his research team have been supported for many years by NCI, DOD breast and prostate cancer initiatives, various foundations including The American Cancer Society, The Whitaker Foundation, and The Mary Kay Ash Foundation and most recently CPRIT. Dr. Mason’s primary research interest is prognostic radiology- developing and implementing methods for predicting optimal cancer therapy and assessing early response to treatment. Current investigations focus on development of oxygen sensitive MRI in pre-clinical breast, prostate and lung cancer as well as translation to human lung and prostate cancer. Dr. Mason is a recognized expert in the development of novel MR and optical reporter starategies with notable innovations in 19F NMR. Recent pre-clinical innovations include dynamic bioluminescent imaging related to vascular disputing agents and in vivo chemiluminescent imaging. Ongoing projects focus on novel vascular disrupting agents and assessment of pathophysiology of tumor response to therapy.
- University of Cambridge (1983), Natural Sciences
- Graduate School
- University of Cambridge (1986), Organic Chemistry
- Application of imaging methods to tumor development and response to therapy; development of NMR reporter molecules as probes of physiology and gene transfection; detoxification of xenobiotica; MR miscroscopy and tissue microstructure.
- Bioluminescent imaging
- gene therapy
- NMR- MRI
- GdDO3NI, a nitroimidazole-based T 1 MRI contrast agent for imaging tumor hypoxia in vivo.
- Gulaka PK, Rojas-Quijano F, Kovacs Z, Mason RP, Sherry AD, Kodibagkar VD J. Biol. Inorg. Chem. 2013 Nov
- Synthesis of a 2-aryl-3-aroyl indole salt (OXi8007) resembling combretastatin A-4 with application as a vascular disrupting agent.
- Hadimani MB, Macdonough MT, Ghatak A, Strecker TE, Lopez R, Sriram M, Nguyen BL, Hall JJ, Kessler RJ, Shirali AR, Liu L, Garner CM, Pettit GR, Hamel E, Chaplin DJ, Mason RP, Trawick ML, Pinney KG J. Nat. Prod. 2013 Sep 76 9 1668-78
- Simultaneous measurement of tissue oxygen level-dependent (TOLD) and blood oxygenation level-dependent (BOLD) effects in abdominal tissue oxygenation level studies.
- Ding Y, Mason RP, McColl RW, Yuan Q, Hallac RR, Sims RD, Weatherall PT J Magn Reson Imaging 2013 Jun
- Novel S-Gal(®) analogs as (1)H MRI reporters for in vivo detection of ß-galactosidase.
- Gulaka PK, Yu JX, Liu L, Mason RP, Kodibagkar VD Magn Reson Imaging 2013 Apr
- New frontiers and developing applications in (19)F NMR.
- Yu JX, Hallac RR, Chiguru S, Mason RP Prog Nucl Magn Reson Spectrosc 2013 Apr 70 25-49
- A noninvasive tumor oxygenation imaging strategy using magnetic resonance imaging of endogenous blood and tissue water.
- Zhang Z, Hallac RR, Peschke P, Mason RP Magn Reson Med 2013 Feb
- Blood oxygenation level-dependent (BOLD) contrast magnetic resonance imaging (MRI) for prediction of breast cancer chemotherapy response: A pilot study.
- Jiang L, Weatherall PT, McColl RW, Tripathy D, Mason RP J Magn Reson Imaging 2012 Nov
- 6-Trifluoromethylpyridoxine: novel (19)F NMR pH indicator for in vivo detection.
- Yu JX, Cui W, Bourke VA, Mason RP J. Med. Chem. 2012 Aug 55 15 6814-21
- Novel Fe(3+)-Based (1)H MRI ß-Galactosidase Reporter Molecules**
- Yu JX, Gulaka PK, Liu L, Kodibagkar VD, Mason RP Chempluschem 2012 May 77 5 370-378
- Dual (19)F/(1)H MR Gene Reporter Molecules for in Vivo Detection of ß-Galactosidase.
- Yu JX, Kodibagkar VD, Hallac RR, Liu L, Mason RP Bioconjug. Chem. 2012 Mar 23 3 596-603
19F NMR: clinical and molecular imaging applications. In Fluorine in Pharmaceutical and Medicinal Chemistry: From Biophysical Aspects to Clinical Applications
V. D. Kodibagkar, R. Hallac, D. Zhao, J.-X. Yu, and R. P. Mason (2012). London, World Scientific Publishing Company
Non-Invasive Physiology and Pharmacology Using 19F Magnetic Resonance. In FLOURINE AND HEALTH
J.X. Yu, W. Cui, D. Zhao, and R. P. Mason (May 2008). Elsevier B.V.
Fluorocarbon Agents for Quantitative Multimodal Molecular Imaging and Targeted Therapeutics. In Molecular Imaging: Principles and Practice
S. A. Wickline, R. P. Mason, S. D. Caruthers, J. Chen, P. M. Winter, M. S. Hughes, G. M. Lanza (2010). People?s Medical Publishing House
MRI Hypoxia Measurements. In Functional Imaging in Oncology
S. Remmele, R. P. Mason, and J. P.B. O?Connor (2014). Heidelberg, Springer-Verlag
Innovative applications of reporter genes and gene reporters in prostate cancer. In Prostate Cancer Cells: Detection, Growth and Treatment
L. Liu, M. K. Alhasan, W. Cui, J. Magnusson, and R. P. Mason (2013). Hauppauge, NY, Nova Science Publishers
Honors & Awards
- Outstanding Teacher Award: International Society for Magnetic Resonance in Medicine (ISMRM), Honolulu, HI
Beyond Proton MRI: 19F MRI & More (2017)
- Outstanding Teacher Award: International Society for Magnetic Resonance in Medicine (ISMRM), Singapore
- Visiting Professor to the Hubei University of Medicine (HUM)
Famous Scientists Lecture Program in Hubei Province (2015-2015)
- Fellow of Royal Society of Chemistry
Chartered Scientist designation of the Science Council (2004)
- Lyndon Baines Johnson Award
American Heart Association (Texas Affiliate) (1993)
- Young Investigator Award at 5th International Society of Blood Substitutes Meeting
Presentation: Tumor oxygen tension: Measurement using OxygentTM as a 19F NMR probe at 4.7 T (1993)
Chartered Chemist of the Royal Society of Chemistry (1987)
- American Journal of Nuclear Medicine and Molecular Imaging (2011)
- Imaging in Medicine (2009)
- Letters in Drug Design & Discovery (2005)
- American Association for Cancer Research (1993)
- International Society of Magnetic Resonance in Medicine (1990)
- Royal Society of Chemistry (1987)